PL1613656T3 - Przeciwciała modyfikujące przebieg choroby nowotworowej - Google Patents

Przeciwciała modyfikujące przebieg choroby nowotworowej

Info

Publication number
PL1613656T3
PL1613656T3 PL04724505T PL04724505T PL1613656T3 PL 1613656 T3 PL1613656 T3 PL 1613656T3 PL 04724505 T PL04724505 T PL 04724505T PL 04724505 T PL04724505 T PL 04724505T PL 1613656 T3 PL1613656 T3 PL 1613656T3
Authority
PL
Poland
Prior art keywords
antibodies
cancer
disease modifying
cancerous disease
modifying antibodies
Prior art date
Application number
PL04724505T
Other languages
English (en)
Inventor
David S F Young
Susan E Hahn
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PL1613656T3 publication Critical patent/PL1613656T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL04724505T 2003-04-14 2004-03-31 Przeciwciała modyfikujące przebieg choroby nowotworowej PL1613656T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/413,755 US6794494B1 (en) 2003-04-14 2003-04-14 Cancerous disease modifying antibodies
PCT/CA2004/000481 WO2004089989A1 (en) 2003-04-14 2004-03-31 Cancerous disease modifying antibodies
EP04724505A EP1613656B1 (en) 2003-04-14 2004-03-31 Cancerous disease modifying antibodies

Publications (1)

Publication Number Publication Date
PL1613656T3 true PL1613656T3 (pl) 2007-04-30

Family

ID=32990305

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04724505T PL1613656T3 (pl) 2003-04-14 2004-03-31 Przeciwciała modyfikujące przebieg choroby nowotworowej

Country Status (16)

Country Link
US (1) US6794494B1 (pl)
EP (2) EP1613656B1 (pl)
JP (1) JP2007523838A (pl)
CN (1) CN100588662C (pl)
AT (1) ATE348112T1 (pl)
AU (1) AU2004228078A1 (pl)
CA (1) CA2521375A1 (pl)
CY (1) CY1106455T1 (pl)
DE (1) DE602004003689T2 (pl)
DK (1) DK1613656T3 (pl)
ES (1) ES2278309T3 (pl)
NZ (1) NZ542927A (pl)
PL (1) PL1613656T3 (pl)
PT (1) PT1613656E (pl)
SI (1) SI1613656T1 (pl)
WO (1) WO2004089989A1 (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004005351A2 (en) * 2002-07-04 2004-01-15 Oncomab Gmbh Neoplasm specific antibodies and uses thereof
US20080025977A1 (en) * 2003-04-14 2008-01-31 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of CD59
US7195764B2 (en) * 2003-04-14 2007-03-27 Arius Research Inc. Cancerous disease modifying antibodies
US20080213169A1 (en) * 2003-04-14 2008-09-04 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of CD59
US20060140963A1 (en) * 2003-04-14 2006-06-29 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of CD59
US7348413B2 (en) * 2004-02-26 2008-03-25 Arius Research Inc. Cancerous disease modifying antibodies
US7456258B2 (en) 2005-08-02 2008-11-25 Arius Research, Inc. Cancerous disease modifying antibodies
US7452978B2 (en) * 2005-08-02 2008-11-18 Arius Research, Inc. Cancerous disease modifying antibodies
US7494648B2 (en) 2005-08-02 2009-02-24 Hoffmann-La Roche Inc. Cancerous disease modifying antibodies
US8003761B2 (en) * 2007-01-23 2011-08-23 Hoffmann-La Roche Inc. Cancerous disease modifying antibodies
CA2731129A1 (en) * 2008-07-17 2010-01-21 Helen P. Findlay Cancerous disease modifying antibodies
CA2791652C (en) 2010-03-02 2018-06-12 Kyowa Hakko Kirin Co., Ltd. Modified antibody composition
AU2015334886B9 (en) 2014-10-23 2021-07-08 Innate Pharma Treatment of cancers using anti-NKG2A agents
AU2019412489A1 (en) 2018-12-26 2021-06-10 Innate Pharma Leucocyte immunoglobulin-like receptor 2 neutralizing antibodies

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4828991A (en) 1984-01-31 1989-05-09 Akzo N.V. Tumor specific monoclonal antibodies
US4753894A (en) * 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
EP0199141A3 (en) * 1985-04-19 1988-07-20 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies to human gastrointestinal cancer
NZ222509A (en) 1986-11-19 1993-03-26 Oncogen Hybridoma cell line producing antibodies binding to tumour-associated mucin antigen
US4861581A (en) 1986-12-05 1989-08-29 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
US5338832A (en) * 1987-07-02 1994-08-16 Akzo N.V. Antigen recognized by MCA 16-88
US5171665A (en) 1989-04-17 1992-12-15 Oncogen Monoclonal antibody to novel antigen associated with human tumors
US6020145A (en) 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
EP0539970B1 (en) 1991-10-30 1999-05-26 Idemitsu Kosan Company Limited Methods for producing human lymphocytes and human monoclonal antibodies, and human monoclonal antibodies produced thereby
ATE419355T1 (de) * 1992-02-06 2009-01-15 Novartis Vaccines & Diagnostic Marker für krebs und biosynthetisches bindeprotein dafür
IL105008A0 (en) 1992-03-13 1993-07-08 Yeda Res & Dev Double transfectants of mhc genes as cellular vaccines for immunoprevention of tumor metastasis
WO1994018562A1 (en) 1993-02-05 1994-08-18 Epigen, Inc. Human carcinoma antigen (hca), hca antibodies, hca immunoassays, methods of imaging and therapy
EP1018518A2 (en) 1994-06-24 2000-07-12 Vladimir P. Torchilin Use of autoantibodies for tumor therapy and prophylaxis
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US6376654B1 (en) * 1999-08-13 2002-04-23 Molecular Discoveries, Llc Myeloma cell and ovarian cancer cell surface glycoproteins, antibodies thereto, and uses thereof
US6180357B1 (en) * 1999-10-08 2001-01-30 Arius Research, Inc. Individualized patient-specific anti-cancer antibodies
PT2163256E (pt) * 2001-05-11 2015-11-20 Ludwig Inst For Cancer Res Ltd Proteínas de ligação específica e suas utilizações

Also Published As

Publication number Publication date
CN1802387A (zh) 2006-07-12
CN100588662C (zh) 2010-02-10
EP1613656B1 (en) 2006-12-13
US6794494B1 (en) 2004-09-21
WO2004089989A1 (en) 2004-10-21
AU2004228078A1 (en) 2004-10-21
CA2521375A1 (en) 2004-10-21
EP1613656A1 (en) 2006-01-11
EP1757620A3 (en) 2007-11-21
ATE348112T1 (de) 2007-01-15
ES2278309T3 (es) 2007-08-01
DE602004003689T2 (de) 2007-10-04
SI1613656T1 (sl) 2007-04-30
PT1613656E (pt) 2007-02-28
DK1613656T3 (da) 2007-03-12
EP1757620A2 (en) 2007-02-28
CY1106455T1 (el) 2011-10-12
NZ542927A (en) 2008-04-30
JP2007523838A (ja) 2007-08-23
DE602004003689D1 (de) 2007-01-25

Similar Documents

Publication Publication Date Title
EP1718737A4 (en) ANTIBODIES MODIFYING CANCER DISEASES
WO2007095749A8 (en) Cytotoxicity mediation of cells evidencing surface expression of trop-2
CY1106455T1 (el) Τροποποιητικα αντισωματα καρκινικης νοσου
MX2009007619A (es) Anticuerpos modificadores de una enfermedad cancerigena.
WO2004065422A3 (en) Cancerous disease modifying antibodies
MX2009001015A (es) Anticuerpos modificadores de enfermedad cancerosa.
BRPI0601736A (pt) métodos de terapia adjuvante, método de cura de cáncer de mama não metastático, método de redução de reincidência de doenças, método de instrução de pacientes humanos com cáncer de mama her2-positivo não metastático, método de produção e métodos comerciais
IL146127A0 (en) Conformationally restricted polymine analogs as disease therapies
WO2005012361A3 (en) Antibodies raised against colon carcinomas
MX2009007618A (es) Anticuerpos modificadores de una enfermedad cancerigena.
MX2009007617A (es) Anticuerpos modificadores de una enfermedad cancerigena.
WO2003086456A3 (en) Anti-ck18 monoclonal antibody and therapeutic and diagnostic uses thereof in cancer
CY1108194T1 (el) Μεθοδος παραγωγης κυτταροτοξικων αντικαρκινικων αντισωματων
EP1929034A4 (en) ANTIBODIES CAPABLE OF MODIFYING EVOLUTION OF CANCER DISEASE
MX2009011667A (es) Anticuerpos de modificacion de enfermedad cancerosa.
MX2009001292A (es) Anticuerpos modificadores de enfermedad cancerosa.
MX2009009919A (es) Anticuerpo 010207-01 modificador de la enfermedad del cancer, producido por la linea celular ar51a630.3 del hibridoma.
WO2008058380A8 (en) Cancerous disease modifying antibodies
NO20091459L (no) Cancerose sykdomsmodifiserende antistoffer
AR070279A1 (es) Anticuerpos modificadores de enfermedades cancerosas (cdma)
BRPI0718609A8 (pt) Anticorpos modificadores de doença cancerosa.
AR072750A1 (es) Anticuerpos modificadores de enfermedades cancerosas
AR070280A1 (es) Anticuerpos monoclonales modificadores de enfermedades cancerosas (cdmab)
AR071847A1 (es) Anticuerpos monoclonales modificadores de enfermedades cancerosas
WO2009094751A8 (en) An anti-cancer cytotoxic monoclonal antibody